Fasoracetam (110958-19-5)

E 7, 2021

ʻO Cofttek ka mea hana maikaʻi loa Fasoracetam ka pauka ma Kina. Loaʻa i kā mākou hale hana kahi ʻōnaehana hana hoʻopihapiha piha (ISO9001 & ISO14001), me ka mana hana i kēlā me kēia mahina o 150kg.

 


Kūlana: I ka Production Production
Mokuna: 1kg / ʻeke, 25kg / Drum

Fasoracetam (110958-19-5) Snāʻike

Name: Papakurukama
CAS: 110958-19-5
Purity 98%
Kaulike Molecular: C10H16N2O2
Kaumaha Molecular: 196.250 g / mole
Wahi Manaʻo: 57 ° C
Inoa inoa inoa inoa: (R) -1 - ((5-Oxo-2-pyrrolidinyl) carbonyl) piperidine
Hōʻuluʻulu Manaʻo: Fasoracetam; N- (5-Oxo-D-prolyl) piperidine; NS-105; NFC-1; LAM-105.
InChI Key: GOWRRBABHQUJMX-MRVPVSSYSA-N
Half Ola: 1.5 hola
Palekana: Hoʻopukaʻia ma DMSO
Ke kūlana Mana: 0 - 4 C no ka wā pōkole (mau lā a i mau pule), a i ʻole -20 C no ka wā lōʻihi (mahina)
noi: ʻO Fasoracetam kahi lāʻau akamai a i ʻole nootropic i pili i ka ʻohana racetam kaulana o nā lāʻau.
ʻAno: ʻO ka pauma

 

Fasoracetam (110958-19-5) NMR Spectrum

Fasoracetam (110958-19-5) - NMR Spectrum

Inā makemake ʻoe iā COA, MSDS, HNMR no kēlā me kēia ʻōhua o ka huahana a me nā ʻike ʻē aʻe, e ʻoluʻolu e leka uila i kā mākou luna kūʻai kūʻai.

 

He aha ka Fasoracetam (110958-19-5)?

ʻO Fasoracetam (110958-19-5) ka mea i ʻike ʻia ʻo LAM-105, NFC-1, a me NS-105, he lāʻau akamai a i ʻole nootropic no ka ʻohana racetam ʻohana kaulana loa. Ke ulu wikiwiki nei ʻo Nootropics i ke kaulana mahalo i ko lākou hiki ke hoʻonui i ka hana noʻonoʻo, keu hoʻi nā hana hoʻokō, hoʻoikaika, hoʻomanaʻo, a me ka hana ʻana, i nā kānaka olakino.

 

Nā pono ʻo Fasoracetam (110958-19-5)

Hoʻohui maikaʻi a me ka noʻonoʻo

Hiki i ka Fasoracetam ke hoʻohana i nā pae Choline i ka lolo, e kōkua ana i nā mea hoʻohana e noʻonoʻo pono a ma ke kiko, me ka ʻole o ka pono e hoʻohana i nā mea hoʻonāukiuki hou aʻe. ʻAʻole like me nā mea hoʻonāukiuki, hiki i kēia nootropic ke hoʻomau i ka noʻonoʻo a hana i nā hana i mua ou me ka manaʻo ʻole e hele wāwae e hoʻokuʻu i ka ikehu kino i kūkulu ʻia. I nā ʻōlelo maʻalahi, ʻike ʻoe i ka mālie a hoʻomau i ka nānā i kāu hana.

Hiki i nā kiʻekiʻe koline ke alakaʻi pū i ka hoʻokau hoʻonui. ʻO kēia ka mea e hiki ke hoʻohana i nā mea hoʻohana o kēia lāʻau lapaʻau i ke aʻo ʻana a me ka hoʻohana ʻana i kā lākou ʻike i nā pae kiʻekiʻe.

ʻO ka pauku Fasoracetam kahi lāʻau maikaʻi loa no kēlā me ka mea makemake e hoʻoikaika i kā lākou hana cognitive a hoʻokō i nā hoʻomaikaʻi e pono ai lākou, me ka manaʻo ʻole wired a ʻaʻole hiki ke noho mālie ma kahi hoʻokahi.

ʻO kēia mau pōmaikaʻi Fasoracetam he mea maikaʻi loa no nā poʻe elemakule i loaʻa i ka hāʻule cognitive. Me ka hoʻohana ʻana i fasoracetam, e hiki iā lākou ke kamaʻilio maikaʻi, e ʻike i ka mea e hele nei a puni lākou a ʻike pū kekahi i nā mea o ka noʻonoʻo a me ka hoʻoholo.

 

ʻO ka hōʻemi o ka make a me ke kaumaha

ʻO kekahi pōmaikaʻi Fasoracetam (110958-19-5) ke kōkua i hana ʻokoʻa ia mai nā ʻano lāʻau āpau hopohopo ʻo ia ka mea e hāʻawi i kahi hōʻoluʻolu ʻole a me ka maʻalahi mai ka hopohopo me ka ʻole o ka 'buzz.' Hana kēia i kēia lāʻau ma o kāna hopena ma nā receptor o kā mākou mau neurochemicals influencing ʻelua ʻano nui a glutamate a me GABA.

ʻO kēlā mau poʻe e hopohopo nei e loaʻa ka pūnaehana glutamate over-aktif. ʻO nā mea a fasoracetam e hana ai i ke kaupaona ʻana o kēlā ʻōnaehana. Hoʻohālike aku hoʻi ia i nā mea hoʻokele o ka GABA i luna, no laila ke hāʻawi ʻana i ka hopena calming i kaʻa ʻole ʻia mai e ka hiamoe.

ʻAʻole palena ʻia nā hopena kūpono o ka pauku fasoracetam i kanaka. Ua haʻi aku kekahi loea fasoracetam nootropics he mau holoholona i hōʻike i ka hiki ke mālama i nā kūlana paʻakikī me ka mālie ma hope o ka lawe ʻana i ka lāʻau lapaʻau i ka wā o ka hoʻāʻo.

 

Fasoracetam (110958-19-5) hana?

Hoʻohui maikaʻi

ʻAʻole koke ke ʻano o ka hoʻomaikaʻi ʻana i nā hopena o ka fasoracetam. Hoʻohana ʻo ia i ka lawe ʻana mai i kahi kanaka i kahi kūlana ʻoi aku ka maikaʻi o ka noʻonoʻo. ʻO kēlā me kēia manawa i ka mea hoʻohana e hoʻonui i ka Fasoracetam supplementation, hoʻolōʻihi ka lāʻau lapaʻau i ka pono o nā receptor GABA. Hoʻomaopopo i ka hōʻike mau ʻia i ka hopena o kahi hōʻemi o ka hana i nā mea hoʻokipa GABA e hōʻeha paha i ka haʻahaʻa haʻahaʻa.

Ua koho ʻia kēlā mau hiʻohiʻona e hāpai i ka hana o ke kākāʻā GABA i hiki i nā mea kilokilo hou o nā hoʻohui antidepressant me ka nui o nā mea hiki. ʻO ia ke kumu i hiki ai i ka fasoracetam ke hana maikaʻi loa no nā mea hoʻohana e haʻahaʻa a haʻahaʻa a me ka manaʻo ponoʻī.

Inā ʻoe e ʻike i ka pīhoihoi pili i ka nohona a kaumaha i lalo i nā manawa āpau, hiki i ka fasoracetam ke kōkua iā ʻoe e hōʻoluʻolu a hoʻokau iā ʻoe i kahi kūlana maikaʻi o ka noʻonoʻo a me ka hoʻoikaika. ʻO ka mea kupaianaha loa ʻoiai ma hope o kou hoʻōki ʻana i ka lawe ʻana, e mau ana ka hoʻonui ʻia o kāu mau mea loaʻa ʻo GABA a ʻaʻole ʻoe e hilinaʻi i ka lāʻau e ʻoi aku ka maikaʻi.

 

Hoʻohui hoʻomanaʻo

E like me kā mākou i ʻōlelo ai ma mua, hana ʻo Fasoracetam nootropic i nā kemika i loaʻa i loko o ka lolo, e hoʻopili ana i ka acetylcholine a me choline, a ma o kēia mau hopena, hāʻawi ia i neuroprotection ʻoi aku ka maikaʻi i loko o kā mākou lolo. Hoʻohui ʻia, e like me nā ʻohana Nootropics ʻohana Racetam ʻē aʻe, he mau ʻano e hoʻonui ai i ka paʻa ʻana o ka hoʻomanaʻo.

Ke lawe ʻoe i kēia lāʻau lapaʻau, ʻike hou ʻia ʻoe. Loaʻa iā ʻoe ka mākaukau e hana hou ai i nā hoʻomanaʻo i ka ʻoihana maikaʻi. ʻO ke kumu kēia inā ʻoe e aʻo i kekahi mea ma kēia lāʻau lapaʻau, e loaʻa iā ʻoe ka mana e hoʻomau i kēia ʻike. Hoʻohui maikaʻi, kōkua ia i ka hoʻōla ʻana o ka hanauna kahiko me ka maikaʻi o ka maikaʻi o ka hoʻomanaʻo ʻana a loaʻa iā lākou kahi hoʻomanaʻo maikaʻi.

 

Fasoracetam (110958-19-5) ʻike

ʻAʻole i hoʻopaʻa ʻia ka hopena o kēia lāʻau i ka poʻe kanaka no laila, no laila, ʻaʻohe kumu kuhikuhi no ka palena o fasoracetam.

I nā hoʻokolohua hoʻokolohua e pili ana i nā ʻōpio me ADHD, ua lawelawe waha ʻia ka fasoracetam i hoʻokahi mahele lāʻau mua o 50 mg a 800 mg, a ukali ʻia e nā lāʻau hope i hoʻoulu ʻia e nā hōʻailona ma hope o 400 mg ʻelua manawa i kēlā me kēia lā no ʻehā pule. Hoʻokahi psychasut fasoracetam i lawe i 10mg i kēlā me kēia lā sublingually a hiki iā ia ke hoʻokō i nā hopena i makemake ʻia.

I kahi hoʻokolohua hoʻokolohua e pili ana i nā kāne Kepani 14, hāʻawi ʻia i nā lā o 100 mg i kēlā me kēia lā. Ua maikaʻi kēia hana. Eia nō naʻe, he hui ikaika loa ka fasoracetam, a ʻo nā dosages ma lalo o 20 mg i lawelawe ʻia i hoʻokahi a ʻelua mau manawa i kēlā me kēia lā i hōʻoia ʻia e like me ka maikaʻi no kekahi mau mea hoʻohana.

Me nā Nootropics āpau a like pū me fasoracetam, he naʻauao ke hoʻomaka me nā mea hana haʻahaʻa haʻahaʻa a hoʻonui iki e like me ka mea e koi ʻia ana.

 

Papakurukama ka lehu no ka kuai(Kahi e kūʻai ai i ka pauka Fasoracetam i ka nui)

ʻOliʻoli kā mākou ʻoihana i nā pilina lōʻihi e ko mākou mea kūʻai aku no ka mea ke nānā aku nei mākou i ka lawelawe o ka mea kūʻai aku a hāʻawi i nā huahana maikaʻi. Inā makemake ʻoe i kā mākou huahana, maʻalahi mākou me ka hoʻokaʻawale ʻana i nā kauoha e kūpono i kāu pono kūikawā a me ko mākou wikiwiki wikiwiki i nā kauoha e hōʻoia ʻoe e hoʻāʻo nui i kā mākou huahana i ka manawa. Hoʻomaopopo pū mākou i nā lawelawe i hoʻohui ʻia. Loaʻa mākou i nā nīnau a me ka ʻike e kākoʻo i kāu ʻoihana.

He mea hoʻolako paʻahana ʻoihana Fasoracetam mākou no kekahi mau makahiki, hoʻolako mākou i nā huahana me ke kumukūʻai hoʻokūkū, a ʻo kā mākou huahana ke kiʻekiʻe kiʻekiʻe a ke hana nei i nā hoʻokolohua koʻikoʻi, kūʻokoʻa e ʻike pono ka palekana no ka lawe ʻana a puni ka honua.

 

E hoʻomaopopo '

[1] Ogasawara T, Itoh Y, Tamura M, et al. Ke komo pū ʻana o nā ʻōnaehana cholinergic a me GABAergic i ka hoʻohuli ʻana i ka hoʻoliʻiliʻi hoʻomanaʻo e NS-105, kahi mea hoʻonui i ka ʻike. ʻO Pharmacol Biochem Behav. 1999; 64 (1): 41-52. hana: 10.1016 / s0091-3057 (99) 00108-2

[2] Elia, J., Ungal, G., Kao, C. et al. ʻO Fasoracetam i nā ʻōpio me ADHD a me nā ʻōnaehana ʻōnaehana glutamatergic e hōʻoki ana i ka hōʻailona neʻe mGluR neurotransmitter. Nat Commun 9, 4 (2018).

[3] Foran E, Trotti D. Glutamate nā halihali a me ke ala excitotoxic i ka hoʻohaʻahaʻa neuron motor ma ka amyotrophic lateral sclerosis. Hōʻailona Antioxid Redox. 2009; 11 (7): 1587-1602. hana: 10.1089 / ars.2009.2444